Frank D. Lee

Mr. Lee has more than 25 years of experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industries. He currently serves as President and Chief Executive Officer of Forma Therapeutics (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers. Prior to joining Forma, Mr. Lee spent 13 years at Genentech, where he was most recently Senior Vice President of global product strategy. Previously, as Vice President of Genentech’s HER2/breast cancer franchise, he was responsible for U.S. P&L for Herceptin®, Perjeta® and Kadcyla®, driving revenues over $4 billion and launching the first HER2 neoadjuvant indication for early HER2 breast cancer patients. Previously, as Vice President of oral oncolytics at Genentech, Mr. Lee held P&L responsibility for Tarceva®, Zelboraf®, Erivedge®, and Xeloda®, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma, and establishing a new treatment option for patients with advanced basal cell carcinoma. Prior to joining Genentech, Mr. Lee spent approximately 13 years at Novartis, Janssen and Eli Lilly. Mr. Lee earned a B.E. in Chemical Engineering from Vanderbilt University and an M.B.A. from the Wharton Graduate School of Business at the University of Pennsylvania.